Autolus Therapeutics announce new time for investor call to discuss data presented at the 63rd ASH Annual Meeting & Exposition

Conference Call and Webcast to be held on Monday, December 13, 2021 at 8:00 am ET / 1:00 pm GMT

LONDON, Dec. 06, 2021 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced it will hold a conference call to discuss the data being presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, being held between December 11-14, 2021. Note this is a change to the timing announced previously.

New timing of investor call
Management will host a conference call and webcast on Monday, December 13, 2021, at 8:00 am ET/1:00 pm GMT to discuss the ASH data. To listen to the webcast and view the accompanying slide presentation, please go to the events section of Autolus’ website.

Conference Dial in:

  • United States and Canada (866) 679-5407
  • International (409) 217-8320
  • Conference ID 31044873

A replay will be available for one week following the call

  • United States and Canada (855) 859-2056
  • International (404) 537-3406
  • Conference ID 31044873

About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, please visit

Back to News and insights